B-intervention	0	11	Fulvestrant
I-intervention	12	16	plus
I-intervention	17	28	palbociclib
O	29	35	versus
B-control	36	47	fulvestrant
I-control	48	52	plus
I-control	53	60	placebo
O	61	64	for
O	65	74	treatment
O	75	77	of
O	78	85	hormone
O	85	86	-
O	86	94	receptor
O	94	95	-
O	95	103	positive
O	103	104	,
O	105	109	HER2
O	109	110	-
O	110	118	negative
O	119	129	metastatic
O	130	136	breast
O	137	143	cancer
O	144	148	that
O	149	159	progressed
O	160	162	on
O	163	171	previous
O	172	181	endocrine
O	182	189	therapy
O	190	191	(
O	191	197	PALOMA
O	197	198	-
O	198	199	3
O	199	200	)
O	200	201	:
O	202	207	final
O	208	216	analysis
O	217	219	of
O	220	223	the
O	224	235	multicentre
O	235	236	,
O	237	243	double
O	243	244	-
O	244	249	blind
O	249	250	,
O	251	256	phase
O	257	258	3
O	259	269	randomised
O	270	280	controlled
O	281	286	trial
O	286	287	.

O	288	290	In
O	291	294	the
O	295	301	PALOMA
O	301	302	-
O	302	303	3
O	304	309	study
O	309	310	,
O	311	314	the
O	315	326	combination
O	327	329	of
O	330	333	the
O	334	338	CDK4
O	339	342	and
O	343	347	CDK6
O	348	357	inhibitor
O	358	369	palbociclib
O	370	373	and
O	374	385	fulvestrant
O	386	389	was
O	390	400	associated
O	401	405	with
O	406	417	significant
O	418	430	improvements
O	431	433	in
O	434	445	progression
O	445	446	-
O	446	450	free
O	451	459	survival
O	460	468	compared
O	469	473	with
O	474	485	fulvestrant
O	486	490	plus
O	491	498	placebo
O	499	501	in
O	502	510	patients
O	511	515	with
O	516	526	metastatic
O	527	533	breast
O	534	540	cancer
O	540	541	.

O	542	556	Identification
O	557	559	of
O	560	568	patients
O	569	573	most
O	574	582	suitable
O	583	586	for
O	587	590	the
O	591	599	addition
O	600	602	of
O	603	614	palbociclib
O	615	617	to
O	618	627	endocrine
O	628	635	therapy
O	636	641	after
O	642	648	tumour
O	649	659	recurrence
O	660	662	is
O	663	670	crucial
O	671	674	for
O	675	684	treatment
O	685	697	optimisation
O	698	700	in
O	701	711	metastatic
O	712	718	breast
O	719	725	cancer
O	725	726	.

O	727	729	We
O	730	735	aimed
O	736	738	to
O	739	746	confirm
O	747	750	our
O	751	758	earlier
O	759	767	findings
O	768	772	with
O	773	777	this
O	778	786	extended
O	787	793	follow
O	793	794	-
O	794	796	up
O	797	800	and
O	801	805	show
O	806	809	our
O	810	817	results
O	818	821	for
O	822	830	subgroup
O	831	834	and
O	835	844	biomarker
O	845	853	analyses
O	853	854	.

O	855	857	In
O	858	862	this
O	863	874	multicentre
O	874	875	,
O	876	882	double
O	882	883	-
O	883	888	blind
O	888	889	,
O	890	900	randomised
O	901	906	phase
O	907	908	3
O	909	914	study
O	914	915	,
O	916	921	women
O	922	926	aged
B-age	927	929	18
I-age	930	935	years
I-age	936	938	or
I-age	939	944	older
B-eligibility	945	949	with
I-eligibility	950	957	hormone
I-eligibility	957	958	-
I-eligibility	958	966	receptor
I-eligibility	966	967	-
I-eligibility	967	975	positive
I-eligibility	975	976	,
I-eligibility	977	981	HER2
I-eligibility	981	982	-
I-eligibility	982	990	negative
I-eligibility	991	1001	metastatic
I-eligibility	1002	1008	breast
I-eligibility	1009	1015	cancer
I-eligibility	1016	1020	that
I-eligibility	1021	1024	had
I-eligibility	1025	1035	progressed
I-eligibility	1036	1038	on
I-eligibility	1039	1047	previous
I-eligibility	1048	1057	endocrine
I-eligibility	1058	1065	therapy
O	1066	1070	were
O	1071	1081	stratified
O	1082	1084	by
O	1085	1096	sensitivity
O	1097	1099	to
O	1100	1108	previous
O	1109	1117	hormonal
O	1118	1125	therapy
O	1125	1126	,
O	1127	1137	menopausal
O	1138	1144	status
O	1144	1145	,
O	1146	1149	and
O	1150	1158	presence
O	1159	1161	of
O	1162	1170	visceral
O	1171	1181	metastasis
O	1182	1184	at
O	1185	1188	144
O	1189	1196	centres
O	1197	1199	in
O	1200	1202	17
O	1203	1212	countries
O	1212	1213	.

O	1214	1222	Eligible
O	1223	1231	patients
O	1231	1232	-
O	1232	1234	ie
O	1234	1235	,
O	1236	1239	any
O	1240	1250	menopausal
O	1251	1257	status
O	1257	1258	,
O	1259	1266	Eastern
O	1267	1278	Cooperative
O	1279	1287	Oncology
O	1288	1293	Group
O	1294	1305	performance
O	1306	1312	status
O	1313	1314	0
O	1314	1315	-
O	1315	1316	1
O	1316	1317	,
O	1318	1328	measurable
O	1329	1336	disease
O	1337	1339	or
O	1340	1344	bone
O	1345	1352	disease
O	1353	1357	only
O	1357	1358	,
O	1359	1362	and
O	1363	1370	disease
O	1371	1378	relapse
O	1379	1381	or
O	1382	1393	progression
O	1394	1399	after
O	1400	1408	previous
O	1409	1418	endocrine
O	1419	1426	therapy
O	1427	1430	for
O	1431	1439	advanced
O	1440	1447	disease
O	1448	1454	during
O	1455	1464	treatment
O	1465	1467	or
O	1468	1474	within
O	1475	1477	12
O	1478	1484	months
O	1485	1487	of
O	1488	1498	completion
O	1499	1501	of
O	1502	1510	adjuvant
O	1511	1518	therapy
O	1518	1519	-
O	1519	1523	were
O	1524	1532	randomly
O	1533	1541	assigned
O	1542	1543	(
O	1543	1544	2
O	1544	1545	:
O	1545	1546	1
O	1546	1547	)
O	1548	1551	via
O	1552	1553	a
O	1554	1565	centralised
O	1566	1577	interactive
O	1578	1581	web
O	1581	1582	-
O	1582	1587	based
O	1588	1591	and
O	1592	1597	voice
O	1597	1598	-
O	1598	1603	based
O	1604	1617	randomisation
O	1618	1624	system
O	1625	1627	to
O	1628	1635	receive
O	1636	1640	oral
O	1641	1652	palbociclib
O	1653	1654	(
O	1654	1657	125
O	1658	1660	mg
O	1661	1666	daily
O	1667	1670	for
O	1671	1672	3
O	1673	1678	weeks
O	1679	1687	followed
O	1688	1690	by
O	1691	1692	a
O	1693	1697	week
O	1698	1701	off
O	1702	1706	over
O	1707	1709	28
O	1709	1710	-
O	1710	1713	day
O	1714	1720	cycles
O	1720	1721	)
O	1722	1726	plus
O	1727	1730	500
O	1731	1733	mg
O	1734	1745	fulvestrant
O	1746	1747	(
O	1747	1760	intramuscular
O	1761	1770	injection
O	1771	1773	on
O	1774	1778	days
O	1779	1780	1
O	1781	1784	and
O	1785	1787	15
O	1788	1790	of
O	1791	1796	cycle
O	1797	1798	1
O	1798	1799	;
O	1800	1804	then
O	1805	1807	on
O	1808	1811	day
O	1812	1813	1
O	1814	1816	of
O	1817	1827	subsequent
O	1828	1830	28
O	1830	1831	-
O	1831	1834	day
O	1835	1841	cycles
O	1841	1842	)
O	1843	1845	or
O	1846	1853	placebo
O	1854	1858	plus
O	1859	1870	fulvestrant
O	1870	1871	.

O	1872	1875	The
O	1876	1883	primary
O	1884	1892	endpoint
O	1893	1896	was
O	1897	1909	investigator
O	1909	1910	-
O	1910	1918	assessed
B-outcome-Measure	1919	1930	progression
I-outcome-Measure	1930	1931	-
I-outcome-Measure	1931	1935	free
I-outcome-Measure	1936	1944	survival
O	1944	1945	.

O	1946	1954	Analysis
O	1955	1958	was
O	1959	1961	by
O	1962	1971	intention
O	1972	1974	to
O	1975	1980	treat
O	1980	1981	.

O	1982	1984	We
O	1985	1989	also
O	1990	1998	assessed
O	1999	2008	endocrine
O	2009	2016	therapy
O	2017	2027	resistance
O	2028	2030	by
O	2031	2039	clinical
O	2040	2050	parameters
O	2050	2051	,
O	2052	2064	quantitative
O	2065	2072	hormone
O	2072	2073	-
O	2073	2081	receptor
O	2082	2092	expression
O	2092	2093	,
O	2094	2097	and
O	2098	2104	tumour
O	2105	2111	PIK3CA
O	2112	2122	mutational
O	2123	2129	status
O	2130	2132	in
O	2133	2144	circulating
O	2145	2148	DNA
O	2149	2151	at
O	2152	2160	baseline
O	2160	2161	.

O	2162	2166	This
O	2167	2172	study
O	2173	2175	is
O	2176	2186	registered
O	2187	2191	with
O	2192	2206	ClinicalTrials
O	2206	2207	.
O	2208	2211	gov
O	2211	2212	,
O	2213	2224	NCT01942135
O	2224	2225	.

O	2226	2233	Between
O	2234	2237	Oct
O	2238	2239	7
O	2239	2240	,
O	2241	2245	2013
O	2245	2246	,
O	2247	2250	and
O	2251	2254	Aug
O	2255	2257	26
O	2257	2258	,
O	2259	2263	2014
O	2263	2264	,
B-total-participants	2265	2268	521
O	2269	2277	patients
O	2278	2282	were
O	2283	2291	randomly
O	2292	2300	assigned
O	2300	2301	,
B-intervention-participants	2302	2305	347
O	2306	2308	to
O	2309	2320	fulvestrant
O	2321	2325	plus
O	2326	2337	palbociclib
O	2338	2341	and
B-control-participants	2342	2345	174
O	2346	2348	to
O	2349	2360	fulvestrant
O	2361	2365	plus
O	2366	2373	placebo
O	2373	2374	.

O	2375	2380	Study
O	2381	2390	enrolment
O	2391	2393	is
O	2394	2400	closed
O	2401	2404	and
O	2405	2412	overall
O	2413	2421	survival
O	2422	2428	follow
O	2428	2429	-
O	2429	2431	up
O	2432	2434	is
O	2435	2437	in
O	2438	2446	progress
O	2446	2447	.

O	2448	2450	By
O	2451	2456	March
O	2457	2459	16
O	2459	2460	,
O	2461	2465	2015
O	2465	2466	,
O	2467	2470	259
B-outcome	2471	2482	progression
I-outcome	2482	2483	-
I-outcome	2483	2487	free
I-outcome	2487	2488	-
I-outcome	2488	2496	survival
I-outcome	2497	2503	events
O	2504	2507	had
O	2508	2516	occurred
O	2517	2518	(
B-iv-bin-abs	2518	2521	145
O	2522	2524	in
O	2525	2528	the
O	2529	2540	fulvestrant
O	2541	2545	plus
O	2546	2557	palbociclib
O	2558	2563	group
O	2564	2567	and
B-cv-bin-abs	2568	2571	114
O	2572	2574	in
O	2575	2578	the
O	2579	2590	fulvestrant
O	2591	2595	plus
O	2596	2603	placebo
O	2604	2609	group
O	2609	2610	)
O	2610	2611	;
O	2612	2618	median
O	2619	2625	follow
O	2625	2626	-
O	2626	2628	up
O	2629	2632	was
O	2633	2634	8
O	2634	2635	·
O	2635	2636	9
O	2637	2643	months
O	2644	2645	(
O	2645	2648	IQR
O	2649	2650	8
O	2650	2651	·
O	2651	2652	7
O	2652	2653	-
O	2653	2654	9
O	2654	2655	·
O	2655	2656	2
O	2656	2657	)
O	2657	2658	.

B-outcome	2659	2665	Median
I-outcome	2666	2677	progression
I-outcome	2677	2678	-
I-outcome	2678	2682	free
I-outcome	2683	2691	survival
O	2692	2695	was
B-iv-cont-median	2696	2697	9
I-iv-cont-median	2697	2698	·
I-iv-cont-median	2698	2699	5
I-iv-cont-median	2700	2706	months
O	2707	2708	(
O	2708	2710	95
O	2710	2711	%
O	2712	2714	CI
O	2715	2716	9
O	2716	2717	·
O	2717	2718	2
O	2718	2719	-
O	2719	2721	11
O	2721	2722	·
O	2722	2723	0
O	2723	2724	)
O	2725	2727	in
O	2728	2731	the
O	2732	2743	fulvestrant
O	2744	2748	plus
O	2749	2760	palbociclib
O	2761	2766	group
O	2767	2770	and
B-cv-cont-median	2771	2772	4
I-cv-cont-median	2772	2773	·
I-cv-cont-median	2773	2774	6
I-cv-cont-median	2775	2781	months
O	2782	2783	(
O	2783	2784	3
O	2784	2785	·
O	2785	2786	5
O	2786	2787	-
O	2787	2788	5
O	2788	2789	·
O	2789	2790	6
O	2790	2791	)
O	2792	2794	in
O	2795	2798	the
O	2799	2810	fulvestrant
O	2811	2815	plus
O	2816	2823	placebo
O	2824	2829	group
O	2830	2831	(
O	2831	2837	hazard
O	2838	2843	ratio
O	2844	2845	0
O	2845	2846	·
O	2846	2848	46
O	2848	2849	,
O	2850	2852	95
O	2852	2853	%
O	2854	2856	CI
O	2857	2858	0
O	2858	2859	·
O	2859	2861	36
O	2861	2862	-
O	2862	2863	0
O	2863	2864	·
O	2864	2866	59
O	2866	2867	,
O	2868	2869	p
O	2869	2870	<
O	2870	2871	0
O	2871	2872	·
O	2872	2876	0001
O	2876	2877	)
O	2877	2878	.

B-outcome	2879	2884	Grade
I-outcome	2885	2886	3
I-outcome	2887	2889	or
I-outcome	2890	2891	4
I-outcome	2892	2899	adverse
I-outcome	2900	2906	events
O	2907	2915	occurred
O	2916	2918	in
B-iv-bin-abs	2919	2922	251
O	2923	2924	(
B-iv-bin-percent	2924	2926	73
I-iv-bin-percent	2926	2927	%
O	2927	2928	)
O	2929	2931	of
B-intervention-participants	2932	2935	345
O	2936	2944	patients
O	2945	2947	in
O	2948	2951	the
O	2952	2963	fulvestrant
O	2964	2968	plus
O	2969	2980	palbociclib
O	2981	2986	group
O	2987	2990	and
B-cv-bin-abs	2991	2993	38
O	2994	2995	(
B-cv-bin-percent	2995	2997	22
I-cv-bin-percent	2997	2998	%
O	2998	2999	)
O	3000	3002	of
B-control-participants	3003	3006	172
O	3007	3015	patients
O	3016	3018	in
O	3019	3022	the
O	3023	3034	fulvestrant
O	3035	3039	plus
O	3040	3047	placebo
O	3048	3053	group
O	3053	3054	.

O	3055	3058	The
O	3059	3063	most
O	3064	3070	common
B-outcome	3071	3076	grade
I-outcome	3077	3078	3
I-outcome	3079	3081	or
I-outcome	3082	3083	4
I-outcome	3084	3091	adverse
I-outcome	3092	3098	events
O	3099	3103	were
B-outcome	3104	3115	neutropenia
O	3116	3117	(
B-iv-bin-abs	3117	3120	223
O	3121	3122	[
B-iv-bin-percent	3122	3124	65
I-iv-bin-percent	3124	3125	%
O	3125	3126	]
O	3127	3129	in
O	3130	3133	the
O	3134	3145	fulvestrant
O	3146	3150	plus
O	3151	3162	palbociclib
O	3163	3168	group
O	3169	3172	and
B-cv-bin-abs	3173	3176	one
O	3177	3178	[
B-cv-bin-percent	3178	3179	1
I-cv-bin-percent	3179	3180	%
O	3180	3181	]
O	3182	3184	in
O	3185	3188	the
O	3189	3200	fulvestrant
O	3201	3205	plus
O	3206	3213	placebo
O	3214	3219	group
O	3219	3220	)
O	3220	3221	,
B-outcome	3222	3229	anaemia
O	3230	3231	(
B-iv-bin-abs	3231	3234	ten
O	3235	3236	[
B-iv-bin-percent	3236	3237	3
I-iv-bin-percent	3237	3238	%
O	3238	3239	]
O	3240	3243	and
B-cv-bin-abs	3244	3249	three
O	3250	3251	[
B-cv-bin-percent	3251	3252	2
I-cv-bin-percent	3252	3253	%
O	3253	3254	]
O	3254	3255	)
O	3255	3256	,
O	3257	3260	and
B-outcome	3261	3271	leucopenia
O	3272	3273	(
B-iv-bin-abs	3273	3275	95
O	3276	3277	[
B-iv-bin-percent	3277	3279	28
I-iv-bin-percent	3279	3280	%
O	3280	3281	]
O	3282	3285	and
B-cv-bin-abs	3286	3289	two
O	3290	3291	[
B-cv-bin-percent	3291	3292	1
I-cv-bin-percent	3292	3293	%
O	3293	3294	]
O	3294	3295	)
O	3295	3296	.

B-outcome	3297	3304	Serious
I-outcome	3305	3312	adverse
I-outcome	3313	3319	events
O	3320	3321	(
O	3321	3324	all
O	3325	3336	causalities
O	3336	3337	)
O	3338	3346	occurred
O	3347	3349	in
B-iv-bin-abs	3350	3352	44
O	3353	3361	patients
O	3362	3363	(
B-iv-bin-percent	3363	3365	13
I-iv-bin-percent	3365	3366	%
O	3366	3367	)
O	3368	3370	of
B-intervention-participants	3371	3374	345
O	3375	3377	in
O	3378	3381	the
O	3382	3393	fulvestrant
O	3394	3398	plus
O	3399	3410	palbociclib
O	3411	3416	group
O	3417	3420	and
B-cv-bin-abs	3421	3423	30
O	3424	3425	(
B-cv-bin-percent	3425	3427	17
I-cv-bin-percent	3427	3428	%
O	3428	3429	)
O	3430	3432	of
B-control-participants	3433	3436	172
O	3437	3445	patients
O	3446	3448	in
O	3449	3452	the
O	3453	3464	fulvestrant
O	3465	3469	plus
O	3470	3477	placebo
O	3478	3483	group
O	3483	3484	.

B-outcome	3485	3491	PIK3CA
I-outcome	3492	3500	mutation
O	3501	3504	was
O	3505	3513	detected
O	3514	3516	in
O	3517	3520	the
O	3521	3527	plasma
O	3528	3531	DNA
O	3532	3534	of
O	3535	3538	129
O	3539	3540	(
O	3540	3542	33
O	3542	3543	%
O	3543	3544	)
O	3545	3547	of
O	3548	3551	395
O	3552	3560	patients
O	3561	3564	for
O	3565	3569	whom
O	3570	3575	these
O	3576	3580	data
O	3581	3585	were
O	3586	3595	available
O	3595	3596	.

O	3597	3604	Neither
O	3605	3611	PIK3CA
O	3612	3618	status
O	3619	3622	nor
O	3623	3630	hormone
O	3630	3631	-
O	3631	3639	receptor
O	3640	3650	expression
O	3651	3656	level
O	3657	3670	significantly
O	3671	3679	affected
O	3680	3689	treatment
O	3690	3698	response
O	3698	3699	.

O	3700	3711	Fulvestrant
O	3712	3716	plus
O	3717	3728	palbociclib
O	3729	3732	was
O	3733	3743	associated
O	3744	3748	with
O	3749	3760	significant
O	3761	3764	and
O	3765	3775	consistent
O	3776	3787	improvement
O	3788	3790	in
O	3791	3802	progression
O	3802	3803	-
O	3803	3807	free
O	3808	3816	survival
O	3817	3825	compared
O	3826	3830	with
O	3831	3842	fulvestrant
O	3843	3847	plus
O	3848	3855	placebo
O	3855	3856	,
O	3857	3869	irrespective
O	3870	3872	of
O	3873	3876	the
O	3877	3883	degree
O	3884	3886	of
O	3887	3896	endocrine
O	3897	3907	resistance
O	3907	3908	,
O	3909	3916	hormone
O	3916	3917	-
O	3917	3925	receptor
O	3926	3936	expression
O	3937	3942	level
O	3942	3943	,
O	3944	3947	and
O	3948	3954	PIK3CA
O	3955	3965	mutational
O	3966	3972	status
O	3972	3973	.

O	3974	3977	The
O	3978	3989	combination
O	3990	3995	could
O	3996	3998	be
O	3999	4009	considered
O	4010	4012	as
O	4013	4014	a
O	4015	4026	therapeutic
O	4027	4033	option
O	4034	4037	for
O	4038	4046	patients
O	4047	4051	with
O	4052	4061	recurrent
O	4062	4069	hormone
O	4069	4070	-
O	4070	4078	receptor
O	4078	4079	-
O	4079	4087	positive
O	4087	4088	,
O	4089	4093	HER2
O	4093	4094	-
O	4094	4102	negative
O	4103	4113	metastatic
O	4114	4120	breast
O	4121	4127	cancer
O	4128	4132	that
O	4133	4136	has
O	4137	4147	progressed
O	4148	4150	on
O	4151	4159	previous
O	4160	4169	endocrine
O	4170	4177	therapy
O	4177	4178	.

O	4179	4185	Pfizer
O	4185	4186	.
